nintedanib, Nintedanib, nintedanib
1199-0378
Phase 3 small_molecule active
Quick answer
nintedanib, Nintedanib, nintedanib for Childhood Interstitial Lung Disease is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Childhood Interstitial Lung Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active